Risk for Cancer-Associated Thrombosis

Dear Colleagues,

Thrombotic complications remain the major sequelae (with respect to morbidity and mortality) of oncologic diseases due to their natural tumor course and treatment-related events, which are going to be discussed in this Special Issue of this journal.

Thrombotic complications may manifest as classical deep vein thrombosis/pulmonary embolism and visceral thrombosis, along with arterial thrombosis and chronic or sometimes acute disseminated intravascular coagulation. Thrombotic events are mainly linked to active cancer and even more with chemotherapy or hormonal and biological therapeutic modalities. Their pathomechanisms share many similarities (i.e., tissue factor activation, etc.), but there are also substantial differences (i.e., cereblons in myeloma, other mechanisms in some cerebral tumors, etc.) and complex issues using biological and different types of cell therapies.

Their treatment modalities are similar, mostly LMWH, increasingly DOAC based, rarely aspirin (e.g., myeloma cereblon-targeting agents), and involve approaches with a growing number of innovative therapeutic modalities.

The traditional approach of recommending protocols by tumor types is still in focus (considering the more or less thrombogenic type of cancers), but the time has come to summarize and conclude thrombogenicity/vascular issues and antithrombotic measures with other treatment trends (e.g., bone marrow transplantation, CAR+T cell interventions, angiogenesis modifiers, immunotherapies, etc.), which are going to be covered in separate chapters of this Special Issue.

Dr. Miklos Udvardy
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.